We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Neuroimaging Effects of Cognitive Remediation Training

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00481156
Recruitment Status : Completed
First Posted : June 1, 2007
Last Update Posted : June 1, 2007
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to examine behavioral and functional brain changes occuring as a result of cognitive remediation training in patients with schizophrenia. Extension and specificity of related changes will also be examined.

Condition or disease Intervention/treatment
Schizophrenia Behavioral: Cognitive Remediation Behavioral: Cognitive Behavioral Social Skills Training

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Study Start Date : September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Working Memory performance
  2. Brain activation

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia or schizoaffective disorder
  • Stable outpatient

Exclusion Criteria:

  • Current drug abuse or dependence
  • History of neurological damage, disorder, or disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481156


Locations
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Minnesota Medical Foundation
Investigators
Principal Investigator: Angus W MacDonald, Ph.D. University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Kelvin O Lim, Ph.D. University of Minnesota - Clinical and Translational Science Institute
More Information

ClinicalTrials.gov Identifier: NCT00481156     History of Changes
Other Study ID Numbers: 0404M58647
CogRehab
First Posted: June 1, 2007    Key Record Dates
Last Update Posted: June 1, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders